VNDA Share Price

Open 13.90 Change Price %
High 14.20 1 Day 0.05 0.36
Low 13.77 1 Week -0.60 -4.12
Close 13.95 1 Month 0.35 2.57
Volume 920329 1 Year 6.62 90.31
52 Week High 18.00
52 Week Low 7.20
VNDA Important Levels
Resistance 2 14.35
Resistance 1 14.18
Pivot 13.97
Support 1 13.72
Support 2 13.55
NASDAQ USA Most Active Stocks
FTR 2.11 -10.59%
FTR 2.11 -10.59%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
BGMD 0.06 20.00%
HAUP 0.06 20.00%
IDRA 2.49 19.14%
CLNT 3.08 16.23%
CGEI 0.36 16.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)

VNDA Technical Analysis 1.5
As on 22nd Mar 2017 VNDA Share Price closed @ 13.95 and we RECOMMEND Buy for LONG-TERM with Stoploss of 13.58 & Sell for SHORT-TERM with Stoploss of 14.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
VNDA Target for March
1st Target up-side 15.5
2nd Target up-side 16.37
3rd Target up-side 17.25
1st Target down-side 13
2nd Target down-side 12.13
3rd Target down-side 11.25
VNDA Other Details
Segment EQ
Market Capital 96253192.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.vandapharmaceuticals.com
VNDA Address
VNDA
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
Phone: 202-734-3400
Fax: 202-296-1450
Interactive Technical Analysis Chart Vanda Pharmaceuticals Inc. ( VNDA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vanda Pharmaceuticals Inc.
VNDA Business Profile
Vanda Pharmaceuticals Inc. (Vanda) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes tasimelteon, a compound for the treatment of circadian rhythm sleep disorders (CRSD), which is in clinical development for Non-24, Fanapt, a compound for the treatment of schizophrenia, the oral formulation of which is being marketed and sold in the United States by Novartis Pharma AG (Novartis), and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist.